Concepts (62)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Burkitt Lymphoma | 1 | 2023 | 335 | 0.770 |
Why?
|
| Antibodies, Bispecific | 1 | 2023 | 246 | 0.730 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 482 | 0.670 |
Why?
|
| Fanconi Anemia | 1 | 2018 | 88 | 0.610 |
Why?
|
| SOS1 Protein | 1 | 2016 | 2 | 0.590 |
Why?
|
| alpha-Fetoproteins | 1 | 2018 | 237 | 0.580 |
Why?
|
| Noonan Syndrome | 1 | 2016 | 26 | 0.580 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2016 | 77 | 0.540 |
Why?
|
| Graft vs Host Disease | 2 | 2023 | 2638 | 0.530 |
Why?
|
| Gene Duplication | 1 | 2016 | 421 | 0.490 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2023 | 6550 | 0.440 |
Why?
|
| Bone Marrow Cells | 1 | 2015 | 943 | 0.400 |
Why?
|
| Interferon-gamma | 1 | 2015 | 1144 | 0.400 |
Why?
|
| Lymphocyte Activation | 1 | 2015 | 1688 | 0.370 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2015 | 1033 | 0.370 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 2796 | 0.360 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 180 | 0.220 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2023 | 362 | 0.180 |
Why?
|
| Anemia, Sickle Cell | 1 | 2021 | 339 | 0.150 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2016 | 172 | 0.140 |
Why?
|
| Recurrence | 1 | 2023 | 4758 | 0.130 |
Why?
|
| CD40 Ligand | 1 | 2015 | 115 | 0.130 |
Why?
|
| CD28 Antigens | 1 | 2015 | 202 | 0.130 |
Why?
|
| CD3 Complex | 1 | 2015 | 314 | 0.120 |
Why?
|
| Biological Assay | 1 | 2015 | 177 | 0.120 |
Why?
|
| Coculture Techniques | 1 | 2015 | 626 | 0.120 |
Why?
|
| Hodgkin Disease | 1 | 2022 | 1429 | 0.110 |
Why?
|
| ras Proteins | 1 | 2016 | 770 | 0.110 |
Why?
|
| Antibodies | 1 | 2015 | 838 | 0.100 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 1046 | 0.100 |
Why?
|
| Cell Survival | 1 | 2015 | 3045 | 0.080 |
Why?
|
| Child | 3 | 2023 | 29154 | 0.080 |
Why?
|
| Cell Line | 1 | 2015 | 5114 | 0.080 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 4744 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2023 | 37905 | 0.070 |
Why?
|
| Humans | 7 | 2023 | 261506 | 0.070 |
Why?
|
| Phenotype | 1 | 2016 | 6295 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2023 | 16273 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2015 | 7226 | 0.050 |
Why?
|
| Transplantation Conditioning | 2 | 2022 | 2238 | 0.050 |
Why?
|
| Carmustine | 1 | 2022 | 214 | 0.050 |
Why?
|
| Alemtuzumab | 1 | 2021 | 198 | 0.050 |
Why?
|
| Unrelated Donors | 1 | 2021 | 304 | 0.040 |
Why?
|
| Busulfan | 1 | 2023 | 764 | 0.040 |
Why?
|
| Melphalan | 1 | 2022 | 834 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 485 | 0.040 |
Why?
|
| Transplantation, Autologous | 1 | 2022 | 1914 | 0.040 |
Why?
|
| Rituximab | 1 | 2022 | 1528 | 0.040 |
Why?
|
| Female | 2 | 2018 | 141928 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 3001 | 0.030 |
Why?
|
| Cytarabine | 1 | 2022 | 1973 | 0.030 |
Why?
|
| Texas | 1 | 2021 | 6311 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 12873 | 0.020 |
Why?
|
| Male | 1 | 2018 | 123000 | 0.020 |
Why?
|
| Infant | 1 | 2023 | 13310 | 0.020 |
Why?
|
| Aged | 2 | 2022 | 70117 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 10035 | 0.010 |
Why?
|
| Young Adult | 1 | 2022 | 21445 | 0.010 |
Why?
|
| Adolescent | 1 | 2022 | 31252 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 15862 | 0.010 |
Why?
|
| Adult | 1 | 2022 | 77950 | 0.010 |
Why?
|
| Middle Aged | 1 | 2022 | 86204 | 0.010 |
Why?
|